0001562180-24-000338.txt : 20240108
0001562180-24-000338.hdr.sgml : 20240108
20240108170040
ACCESSION NUMBER: 0001562180-24-000338
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240104
FILED AS OF DATE: 20240108
DATE AS OF CHANGE: 20240108
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Huang Jane
CENTRAL INDEX KEY: 0001683913
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39527
FILM NUMBER: 24520905
MAIL ADDRESS:
STREET 1: C/O MOURANT OZANNES CORPORATE SERVICES
STREET 2: 94 SOLARIS AVENUE
CITY: CAMANA BAY, GRAND CAYMAN
STATE: E9
ZIP: KY1-1108
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Prelude Therapeutics Inc
CENTRAL INDEX KEY: 0001678660
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 811384762
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 175 INNOVATION BOULEVARD
CITY: WILMINGTON
STATE: DE
ZIP: 19805
BUSINESS PHONE: (302) 467-1280
MAIL ADDRESS:
STREET 1: 175 INNOVATION BOULEVARD
CITY: WILMINGTON
STATE: DE
ZIP: 19805
FORMER COMPANY:
FORMER CONFORMED NAME: Prelude Therapeutics Inc.
DATE OF NAME CHANGE: 20160630
4
1
primarydocument.xml
PRIMARY DOCUMENT
X0508
4
2024-01-04
false
0001678660
Prelude Therapeutics Inc
PRLD
0001683913
Huang Jane
C/O PRELUDE THERAPEUTICS INCORPORATED
175 INNOVATION BOULEVARD
WILMINGTON
DE
19805
false
true
false
false
President, CMO
false
Common Stock
2024-01-04
4
M
false
9375.00
A
49103.00
D
Common Stock
2024-01-04
4
F
false
3844.00
3.77
D
45259.00
D
Restricted Stock Unit
2024-01-04
4
M
false
9375.00
0.00
D
Common Stock
9375.00
84375.00
D
Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer's Common Stock.
Represents shares withheld by the Issuer to satisfy the tax withholding obligation in connection with the vesting of RSUs.
The RSUs were granted on May 2, 2022 and vest according to the reporting person's employment agreement. The RSUs vested as to 1/4 of the total shares on April 4, 2023, and 1/16 of the remaining shares shall vest quarterly thereafter until fully vested, subject to the continued service of the Reporting Person to the Issuer through each vesting date.
/s/ Laurent Chardonnet, Attorney-in-Fact
2024-01-08